第12批国家组织药品集采于7月31日在上海开标[1]。本次集采共有65种药品采购成功，327家企业的521个产品获得拟中选资格[1]。
集采继续发挥降价作用。相较2019年，仿制药每年可为医保节约经费约1600亿元[1]。从历史成效看，药品耗材集采累计节约基金约4400亿元，其中超八成结余资金被用于支持创新药进入医保目录[1]。具体到药品层面，降糖药价格由原来每瓶120元降至8.9元[1]，心脏冠脉支架集采后单价从17000元降至850元[1]。前九批集采的1600余个中选产品中，国产仿制药中标占比达96%，而原研药中标比例仅约4%[1]。即便如此，国内部分药品价格仍存在与国外的差距：5mg氨氯地平在中国价格为3.26元/片，日本为1元/片[1]；20mg立普妥在中国价格为5.8元/片，英国为0.3元/片[1]。
本批集采相比以往进行了多项创新。集采强化了反内卷规则、质量监管要求和基层供应保障[1]。同时，上海推行医保定额报销政策，自今年5月起社区医院可按需自主配备原研药等非中选药品，医保按集采中选价格作为支付标准[1]。此外，医院理论上仍保有30%的采购份额可从未中选产品中自行采购[1]。
China's 12th national organized bulk drug procurement concluded with its opening in Shanghai on July 31, bringing together 327 companies whose 521 products from 65 drug categories secured tentative selection status [1]. The procurement mechanism continues to serve dual purposes: squeezing excess margins from mature generic medications while redirecting savings to support innovative drug coverage under the medical insurance system [1].
The cumulative impact of bulk procurement has become substantial. Since implementation, drug and medical device procurement has generated approximately 440 billion yuan in savings, with over 80 percent of the surplus directed toward expanding innovative drug access in insurance catalogs [1]. Generic drug pricing has undergone dramatic shifts—for instance, a diabetes medication dropped from 120 yuan per bottle to 8.9 yuan, while a coronary stent fell from 17,000 yuan to 850 yuan following procurement reforms [1]. Among the first nine rounds of bulk procurement, domestic generic medications accounted for 96 percent of successful bids, with original research drugs representing only approximately 4 percent [1].
This latest round introduces strengthened measures to prevent market distortion, enhanced quality oversight requirements, and improved supply guarantees for lower-tier healthcare facilities [1]. Shanghai has implemented a fixed-amount medical insurance reimbursement policy allowing community hospitals to independently stock original research drugs and non-selected medications, with patients able to choose based on need [1]. For patients selecting non-selected products, insurance covers costs using the bulk procurement price as the payment standard [1]. Hospitals retain theoretical flexibility to source up to 30 percent of their pharmaceutical needs from products not selected in the procurement [1].